Voyager Therapeutics (NASDAQ: VYGR) is expected to post $21.55M sales for the present quarter on 2nd March by analysts. They have the lowest $7.50M sales estimate while the highest being $32.67M. The company released $32.67M sales in this quarter previous year, indicating a 34% negative annualized growth rate.
On Friday, the company started from $7.69 with the market cap being $288.11M. Their lowest in 1 year is $6.26 while the highest is $14.62. They have a -4.69 PE ratio and 1.80 betas. Their 50-day rolling average price is $8.23 while the 200-day rolling average price is $10.20.
According to the 9th November report, the company had a quarterly EPS earnings of $2.27 that topped the $2.46 consensus estimate by $0.19. They had a 60.61% net negative margin with a 66.46% negative equity return. They had quarterly revenue of $117.84M that surpassed the $43.34M estimate.
Market Ventures Of VYGR Stock
Wedbush demoted the price objective of Voyager Therapeutics shares to $13 from $19 and gave a rating of ‘outperform’. Canaccord Genuity assigned it $14 and reinstated the rating of ‘buy’. Wells Fargo and Co. allotted it $10 and decreased the rating to ‘equal weight’ from ‘overweight’. Oppenheimer demoted the rating to ‘market perform’ from ‘outperform’. BTIG Research decreased it to $18 from $31. The company has a consensus ‘buy’ recommendation with a $14.80 price objective.
Andre Turenne, the CEO, sold off 10,443 VYGR shares at $8.62 EPS worth $90,017.66. Allison Dorval, CFO, sold off 2,942 VYGR shares at $8.62 EPS worth $25,360.04. 23.90% of the stock is owned by insiders.
Great Westlife Assurance lifted their stake by almost 27,328.5% and own $1,362,000 worth of shares. Assenagon Management bought a new position, owning $1,498,000 worth of shares. Federated Hermes raised their holdings by approximately 19%, owning shares priced at $3,301,000. Institutional investors own 78.79% VYGR stock.
